If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 ...

Shares of Eli Lilly and Co. slumped toward their biggest ... due to big misses in sales of anti-obesity drugs Mounjaro and Zepbound. The company said sales of Mounjaro and Zepbound were hurt ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

(George Frey/Reuters) Eli Lilly shares jumped after the drugmaker ... while weight-loss injection Zepbound, which launched late last year, rang in at $1.2 billion. Both figures beating analysts ...

Hims & Hers Health Inc. shares slid over 2.8% on Tuesday and continued declining after-hours trading after Eli Lilly ...

On the other hand, Eli Lilly narrowly topped analysts' revenue expectations, fueled by surging demand for Mounjaro and Zepbound ... 11.4% from previous close. The stock market overreacts to ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, but its stock sank ... for diabetes and Zepbound for weight loss ...